ArticleAdvances in therapy2024

Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.

Hongfan Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.